GGrantIndex
← Leaderboards

Barbara T. Murphy

Mount Sinai School Of Medicine Of Nyu

$15,552,947
Attributed
$17,097,720
Total exposure
11
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $7.1M · FY200520
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$23,122,172 · 12

By mechanism

U01$11,823,221 · 3
UL1$6,024,452 · 1
R01$3,377,089 · 2
T32$870,062 · 1
KL2$855,901 · 1
K08$122,931 · 1

Top collaborators

Most similar at Mount Sinai School Of Medicine Of Nyu

Same institution · by research overlap

Others in their field

Top investigators on “Kidney Transplantation

Research focus

Kidney TransplantationGenomicsKidney AllograftAllograftingTransplantationGenesProtocols DocumentationBiopsyBaseGenotypeProspectiveTransplant RecipientsCollaborationsProgramsImmune ResponseChronic Rejection Of Renal TransplantChronicGeneticMediatingPredispositionGraft SurvivalPathologicCellsPathway Interactions

Grant awards (35)

Genomic risk in clinic care to promote health equity in New York City patients$1,401,278
U01 · FY2020 · HG
An intronic locus determines SHROOM3-expression and potentiates renal allograft fibrosis$381,375
R01 · FY2019 · DK · contact PI
North East Consortium for Transplant outcomes in APOL1 kidney Recipients (NECTAR) Clinical Center$346,138
U01 · FY2019 · DK · contact PI
An intronic locus determines SHROOM3-expression and potentiates renal allograft fibrosis$381,375
R01 · FY2018 · DK · contact PI
North East Consortium for Transplant outcomes in APOL1 kidney Recipients (NECTAR) Clinical Center$269,847
U01 · FY2018 · DK · contact PI
North East Consortium for Transplant outcomes in APOL1 kidney Recipients (NECTAR) Clinical Center$84,826
U01 · FY2018 · DK · contact PI
An intronic locus determines SHROOM3-expression and potentiates renal allograft fibrosis$381,375
R01 · FY2017 · DK · contact PI
North East Consortium for Transplant outcomes in APOL1 kidney Recipients (NECTAR) Clinical Center$286,819
U01 · FY2017 · DK · contact PI
An intronic locus determines SHROOM3-expression and potentiates renal allograft fibrosis$381,375
R01 · FY2016 · DK · contact PI
An intronic locus determines SHROOM3-expression and potentiates renal allograft fibrosis$381,375
R01 · FY2015 · DK · contact PI
Molecular Basis of Renal Disease$182,017
T32 · FY2013 · DK · contact PI
Genomics of Chronic Renal Allograft Rejection$452,794
U01 · FY2012 · AI · contact PI
Molecular Basis of Renal Disease$201,687
T32 · FY2012 · DK · contact PI
Mount Sinai Institutes for Clinical and Translational Sciences$6,024,452
UL1 · FY2011 · RR · contact PI
Mount Sinai Institutes for Clinical and Translational Sciences$855,901
KL2 · FY2011 · RR · contact PI
Molecular Basis of Renal Disease$179,759
T32 · FY2011 · DK · contact PI
Mount Sinai Institutes for Clinical and Translational Sciences$31,104
TL1 · FY2011 · RR · contact PI
Genomics of Chronic Renal Allograft Rejection$1,648,639
U01 · FY2010 · AI · contact PI
Genomics of Chronic Renal Allograft Rejection$317,964
U01 · FY2010 · AI · contact PI
Molecular Basis of Renal Disease$149,908
T32 · FY2010 · DK · contact PI
Genomics of Chronic Renal Allograft Rejection$1,648,225
U01 · FY2009 · AI · contact PI
Genomics of Chronic Renal Allograft Rejection$528,932
U01 · FY2009 · AI · contact PI
Molecular Basis of Renal Disease$156,691
T32 · FY2009 · DK · contact PI
GENOMICS OF CHRONIC RENAL ALLOGRAFT REJECTION$2,936
M01 · FY2009 · RR · contact PI
Genomics of Chronic Renal Allograft Rejection$1,601,146
U01 · FY2008 · AI · contact PI
Genomics of Chronic Renal Allograft Rejection$1,576,679
U01 · FY2007 · AI · contact PI
Genomics of Chronic Renal Allograft Rejection$1,659,934
U01 · FY2006 · AI · contact PI
Immunomodulation by MHC Class II Peptides$296,625
R01 · FY2005 · AI
CLINICAL, IMUNOLOGIC AND PHARMACOLOGIC CONSEQUENCES OF SOLID ORGAN (KIDNEY) T$7,165
M01 · FY2005 · RR
Immunomodulation by MHC Class II Peptides$296,625
R01 · FY2004 · AI
CLINICAL, IMMUNOLOGIC AND PHARMACOLOGIC CONSEQUENCES OF$7,311
M01 · FY2004 · RR
Immunomodulation by MHC Class II Peptides$296,625
R01 · FY2003 · AI
Immunomodulation by MHC Class II Peptides$296,625
R01 · FY2002 · AI
Immunomodulation by MHC Class II Peptides$283,714
R01 · FY2001 · AI
IMMUNOMODULATION BY CLASS II MHC PEPTIDES$122,931
K08 · FY2000 · AI